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obtained clinical trials data for all drugs represented first line therapy for MDD. For
this reason, response rates were down-adjusted to reflect their use as a second-line
therapy, with each response rate being multiplied by a factor obtained from the
STAR*D- trial. Since response rates were reported at a constant rate in clinical
trials, they were converted into “weekly probabilities” of response. Patients enter-
ing second-line monotherapy were not differentiated by switch or add-on.
QuetiapineXR(150mg) was compared with venlafaxineXR(150mg),
escitalopram(10mg) and bupropionXL(300mg), which are considered to be the most
relevant monotherapy comparators in Turkey. One-way sensitivity analyses were
conducted on key model parameters to evaluate the robustness of the model.
RESULTS: The response rates at any time over 52 weeks were 22.5% for quetiap-
ineXR, venlafaxineXR 17.8%, escitalopram 12.6% and bupropionXL 10.7%. In terms
of incremental cost per additional second-line responder, quetiapineXR was found
to be dominant (more effective and less costly) versus venlafaxineXR (-353.55€) and
quetiapineXR was cost-effective (more effective and more costly) versus escitalo-
pram (1785.43€) and bupropionXL (652.90€). The cost per responder of quetiap-
ineXR(48.85€) was less than venlafaxineXR(62.68€), escitalopram(73.20€) and
bupropionXL(95.52€). CONCLUSIONS: This exploratory analysis demonstrated that
in patients with MDD who have failed on previous antidepressant therapy, quetia-
pineXR 150mg as monotherapy was found to be cost-effective compared to escita-
lopram and bupropionXL, in terms of cost per responder, and was dominant when
compared to venlafaxineXR, demonstrating higher efficacy at lower costs.
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OBJECTIVES: In schizophrenia, medication adherence is critical to achieve better
patient outcomes and to avoid relapses, which are responsible for a significant
proportion of total healthcare costs for this chronic illness. The aim of this study
was to assess the cost-effectiveness of olanzapine long-acting injection (OLAI)
compared with risperidone long-acting injection (RLAI) in patients with schizo-
phrenia in Spain. METHODS: A discrete event simulation (DES) model was devel-
oped from a Spanish healthcare system perspective to estimate clinical and eco-
nomic outcomes for patients with schizophrenia over a five year period. Patients
who had earlier responded to oral medication and have a history of relapse due to
adherence problems were considered. These patients faced the option to be treated
with either OLAI or RLAI. In the absence of a head-to-head clinical trial, discontin-
uation and relapse rates were obtained from an indirect comparison of open-label
studies. The model accounted for age, gender, risks of relapse and discontinuation,
relapse management, hospitalization, treatment switching and adverse events.
Direct medical costs (year 2011) and outcomes including relapse avoided, life years
(LYs), and quality-adjusted life years (QALYs) were discounted at a rate of 3%.
RESULTS: When comparing RLAI and OLAI, the model predicts that OLAI would
decrease 5-year costs by €2940, and results in a QALY and LY gain of 0.07 and 0.04,
respectively. Patients on OLAI had fewer relapses compared to RLAI (1.39 vs. 1.82)
and fewer discontinuations (1.22 vs. 1.71). Sensitivity analysis indicated that the
study was robust and conclusions were largely unaffected by changes in a wide
range of parameters. CONCLUSIONS: The present evaluation results in OLAI being
dominant over RLAI, meaning that OLAI represents a more effective and less costly
alternative compared to RLAI in the treatment of patients with schizophrenia in
the Spanish setting.
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OBJECTIVES: To determine the cost-effectiveness of agomelatine for major depres-
sion in adults. METHODS: A hypothetical cohort was simulated from a discrete
event simulation (DES) model developed to describe the course of disease in indi-
viduals. Model inputs included Thai data on disease parameters and costs while
impact measures are derived from systematic reviews and meta-analyses of the
international literature. The costs for treatment of adverse events of these drugs,
insomnia and sexual dysfunction, were taken into account in the model. Antide-
pressant drugs were analyzed for treatment of episodes (12-24 weeks) plus a con-
tinuation phase (6-9 months) and for maintenance treatment over 2 years of follow
up. Results are presented as Thai Baht cost (THB) per quality adjusted life year
(QALY) gained, compared to a matrix comparators (50 % venlafaxine and 50%
escitalopram). RESULTS: Preliminary results show that daily costs for average dose
of agomelatine (25 mg), escitalopram (10 mg) and venlafaxine (150 mg) are 52, 60, 98
THB, respectively. Total cost of agomelatine is 52,000 THB and total cost of matrix
comparator is 76,000 THB. Health benefit measures of agomelatine and the matrix
comparator are almost the same at 2,500 QALY gained. Agomelatine is considered
a cost-effective intervention with an ICER of 400,000 (95% uncertainty range:
410,000- 390,000) THB per QALY gained. The ICER is less than three times Gross
Domestic Product (GDP) per capita in Thailand of 420,000 THB. CONCLUSIONS:
Agomelatine is the most cost-effective treatment option for episodic continuation
and maintenance treatment of major depression when compared with venlaflax-
ine and escitalopram. As recommended by the World Health Organization (WHO)
for cost-effectiveness health intervention, agomelatine is an affordable option for
treatment of major depressive episodes in Thailand.
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OBJECTIVES: Paliperidone ER Extended Release OROS (ER) is a relatively new atyp-
ical antipsychotic for the treatment of schizophrenia. The objective is, based on a
previously published model, to analyze the clinical and economic effects of Pali-
peridone ER in Spain compared to olanzapine oral and aripiprazole. METHODS: An
existing discrete event simulation model was adapted to reflect the treatment of
schizophrenia in Spain in terms of costs, resource use and treatment patterns.
Inputs for the model were derived from clinical trial data, literature search, data-
base analysis, and interviews with local clinical experts. The time horizon is five
years and Spanish discount rates were applied. Outputs included direct medical
costs and Quality Adjusted Life-Years (QALYs). Sensitivity analyses were con-
ducted to assess the uncertainty surrounding incremental outcomes and to iden-
tify model drivers, by performing probabilistic sensitivity analysis (PSA) and ordi-
nary least squares analysis (OLSA). RESULTS: The mean (95% CI) incremental
QALYs compared to olanzapine is 0.033 [-0.14, 0.30] and compared to aripiprazole
0.029 [-0.11,0.30]. The corresponding mean incremental costs (95% CI) are -€ 1,425
[-€ 10,247, €3,084] and -€ 759 [-€ 10,479, € 3,404] respectively. Based on the PSA, the
probability that paliperidone ER is cost-saving and improves QALYs compared to
olanzapine and aripiprazole is 76% and 72% respectively. Paliperidone ER was es-
timated to have 80% and 81% probability of being cost effective compared to olan-
zapine at a willingness to pay of €20,000 and €30,000 and 73% and 74% compared to
aripiprazole respectively. OLSA identified drug acquisition costs, side effects and
risk of relapse to be major model drivers. CONCLUSIONS: Based on differences in
drug acquisition costs, side effects and risk of relapse, the model predicts that in
Spain paliperidone ER provides QALY gains and cost savings compared with oral
olanzapine and aripiprazole with a probability of 76% and 72% respectively.
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OBJECTIVES: To evaluate cost-utility of amisulpride compared with first genera-
tion antipsychotics (FGA) in treatment of schizophrenia in adult patients in Poland.
METHODS: A decision-tree model was used to estimate utilities and costs of treat-
ment of amisulpride therapy in comparison to FGA (antipsychotics, management
of main antipsychotics’ adverse events - extrapyramidal symptoms’ (EPS) and
health care costs). The FGA group included the following drugs: haloperidol, pera-
zine and flupenthixol. Analysis was performed from the National Health Fund
(NHF) perspective with a time horizon of 1 year. The range of possible events in the
model included: therapy discontinuation (regardless of reason), EPS occurrence,
schizophrenia relapse and suicide. Range of events was assumed to be the same for
amisulpride and FGA but probabilities of those events varied between antipsychot-
ics. Based on systematic review of RCTs amisulpride is more effective than FGA in
terms of compliance rate and in reduction of both the risk of relapse and occur-
rence of EPS. A probabilistic sensitivity analysis was performed to estimate the
probability that amisulpride is cost effective in Polish conditions (threshold about
100,000 PLN/QALY). RESULTS: From the NHF perspective amisulpride compared
with FGA was more effective (	QALY  0.004) and it was cheaper (comparing to
flupenthixol) or cost-effective (ICUR1 079/QALY PLN and ICUR31 810/QALY PLN
in comparison to haloperidol and perazine, respectively). The calculated probabil-
ity that amisulpride is more effective than any of FGA was 100%, while the proba-
bility that it is also cost-effective varied between 68% for perazine to 83% for
flupenthixol. CONCLUSIONS: Treatment of schizophrenia with amisulpride is a
cost-effective option in comparison to FGA in Poland. The obtained difference in
QALY is very small, but reduced risk of relapse and necessity of hospitalization due
to better effectiveness of amisulpride and reduced occurrence of EPS results in a
better cost benefit outcome for amisulpride compared to FGA.
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OBJECTIVES: Paliperidone palmitate long-acting injection (PP-LAI) has recently
been approved in Europe for treatment of schizophrenia as an alternative to olan-
zapine pamoate (OLZ-LAI). Their relative cost-effectiveness has not yet been ade-
quately assessed. The purpose was to compare costs and outcomes of these two
LAIs in treating schizophrenia in Norway. METHODS: A previously validated and
published decision analytic model estimating costs and outcomes of treatment
schizophrenia over a 1-year time horizon was adapted to simulate clinical practice
patterns in Norway. Drugs of interest were PP-LAI and OLZ-LAI. Clinical inputs
were derived from the literature and experts, and costs from standard lists. Clinical
outcomes included days in remission, hospitalizations, hospitalized days, and
quality-adjusted life-years (QALYs). Costs were derived from the public health care
provider perspective and reported in 2010 Norwegian kroner (NOK; €17.8 kroner,
USD$15.4 kroner). The pharmacoeconomic outcome was the incremental cost
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per QALY gained. Multiple sensitivity analyses were undertaken to test the robust-
ness of the model including both one-way sensitivity analyses and multivariate
probabilistic sensitivity analyses using Monte Carlo simulations. RESULTS: PP-LAI
treated patients were in remission 249 days and accumulated a total of 0.633 QALYs
at a cost of 89,360 NOK. OLZ-LAI treated patients were in remission 243 days and
accumulated a total of 0.621 QALYs at a cost of 100,888 NOK. The result was that
PP-LAI was the dominant treatment strategy (more effective and less costly). Re-
sults were robust over a wide range of sensitivity analyses tested. The main drivers
of the model included compliance rates and the price of each pharmacotherapy,
with PP-LAI being less costly than OLZ-LAI. CONCLUSIONS: PP-LAI was cost-effec-
tive compared with OLZ-LAI in the treatment of schizophrenia in Norway.
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OBJECTIVES: To use administrative data in a Markov simulation that compares the
cost-effectiveness of depot flupentixol and long-acting risperidone in the treat-
ment of schizophrenia. METHODS: We employed a Markov model to simulate
treatment for schizophrenic patients during 24 cycles with a cycle length of 30
days. The model comprised three non-absorbing states, i.e. inpatient treatment,
outpatient treatment with the patient either being compliant or not, and three
absorbing states, i.e. switching from index medication, death and dropout. Com-
pliance was defined using a refill persistence measure. Treatment costs from the
payer’s perspective, i.e. cost of outpatient, inpatient and pharmaceutical care, and
hospitalization were used as outcomes. Transition probabilities between Markov
states and outcomes for each state were estimated from an administrative dataset
comprising 935 patients who were hospitalized with schizophrenia (ICD-10:F20)
between 2005 and 2008 and who subsequently received depot flupentixol or ris-
peridone. It was adjusted for age, sex, prior hospitalization, prior sick leave, early
retirement, and comorbid conditions according to the Elixhauser score using
multinomial logistic and gamma regression models, respectively. RESULTS: Co-
hort simulation based on 1000 patients on average aged 40.8 years, 55.0% male with
38.0 days of prior annual hospitalization, showed that 102 (266) patients treated
with flupentixol (risperidone) remained in a non-absorbing state after 24 cycles.
Thus switching to other antipsychotics occurred more often with flupentixol. Av-
erage cost of treatment with flupentixol (risperidone) was 544.52 € (1,109.67 €) per
patient and cycle. While patients treated with flupentixol were hospitalized more
often compared to risperidone (5.2% vs. 4.8% per cycle), length of hospitalization
was lower with flupentixol as compared to risperidone (16.11 vs. 16.53 days).
CONCLUSIONS: The effectiveness of depot flupentixol in preventing relapse ap-
pears to be similar to long-acting risperidone. While treatment costs were lower
with flupentixol, switching rates seem to be higher.
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OBJECTIVES: To evaluate the treatment management cost, over 12 weeks, of
asenapine relative to quetiapine, olanzapine, and aripiprazole which are currently
used in Finland and Sweden to treat moderate to severe manic in bipolar I disorder.
METHODS:A cost-minimisation analysis was conducted from a Finnish and Swed-
ish societal perspective. Costs were the only consideration due to similar clinical
efficacy of asenapine demonstrated in active controlled non-inferiority clinical
trial vs olanzapine and through indirect comparisons with quetiapine and aripipra-
zole. Due to significant differences in adverse events and healthcare system costs,
we included management of weight gain, akathesia and insomnia. Patients were
assumed to start treatment as an inpatient for the first month of therapy, and then
followed for two months in an outpatient setting. All direct and indirect resource
use and unit cost estimates were derived from the latest available sources and
literature. No evidence exists suggesting any differences with respect to healthcare
management (e.g. hospitalisation) between treatment strategies. Thus, estimated
resource use and costs applied were assumed the same across treatment strate-
gies. Deterministic sensitivity analyses were conducted to explore uncertainty
around input parameters. RESULTS: The estimated direct cost of treatment and of
the management of adverse events related to treating adults with bipolar I disorder
suffering a manic or mixed episode for 12 weeks with asenapine monotherapy for
Finland and Sweden were respectively: €421 and €670 (SEK 6,044) compared to €502
and €1139 (SEK 10,257; aripiprazole), €141 and €827 (SEK 7,453; quetiapine), and €344
and €957 (SEK 8,616; olanzapine). CONCLUSIONS: Asenapine has been shown to be
cost saving relative to aripiprazole in Finland and to quetiapine, olanzapine, and
aripiprazole in Sweden at the short-term endpoint of 12 weeks. The estimated
treatment cost represented less than 6% of the overall burden of bipolar disorder
from societal perspective.
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OBJECTIVES: prevalence of heroin addiction among Italian population aged 15-64
is 0.8%. Three different drugs are currently available for treating heroin addiction:
methadone, buprenorphine and buprenorphine/naloxone. A monocenter, retro-
spective, one-year follow-up cost-utility analysis (CUA) was performed to compare
buprenorphine/naloxone (211 patients) vs buprenorphine (214 patients) and meth-
adone (512 patients) for heroin addiction detoxification at Department of Addic-
tions, Local Health Authority of Varese, Italy. METHODS: CUA adopted the Depart-
ment of Addictions viewpoint. Clinical, economic and utility data were obtained
from the database of the Department of Addictions and literature. Drugs, bottles for
methadone take-home doses, health care and social services were identified,
quantified and valued in Euro (€) 2009. One-way and probabilistic sensitivity anal-
yses (SAs) were performed. RESULTS: 87.8% of patients are male. Mean (standard
deviation) patients’ age is 37.97.2 years, whereas patients’ first contact with her-
oin dates back to 16.78.5 years. Neither heterogeneity nor sample selection bias
have been detected among treatment groups. Buprenorphine and methadone are
the most and the least costly options (€3257.24 and €2219.47 per patient, respec-
tively). Buprenorphine/naloxone costs €2541.05 per patient. During one-year fol-
low-up patients accrue 0.573 (methadone), 0.599 (buprenorphine) and 0.602 (bu-
prenorphine/naloxone) Quality-Adjusted Life Years (QALYs). Buprenorphine is
strongly dominated by buprenorphine/naloxone and hence ruled out from the base
case CUA. The incremental cost-utility ratio for buprenorphine/naloxone vs meth-
adone is €11,195.12. SAs confirm the robustness of the base case findings. Cost-
Effectiveness Acceptability Curve shows that the probability for buprenorphine/
naloxone to be cost-effective equals 0.58, 0.61 and 0.62 against €25,000, €40,000 and
€50,000 threshold-values, respectively. Cost-Effectiveness Acceptability Frontier
highlights that buprenorphine/naloxone is the optimal alternative from a thresh-
old-value of €11,391.14. CONCLUSIONS: Buprenorphine/naloxone seems advisable
even from an economic point of view, since its incremental cost-utility ratio falls
well within the usual acceptability standards for incremental QALY saved (€25,000-
40,000; €50,000).
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OBJECTIVES: To evaluate the cost-effectiveness of a collaborative stepped care
intervention (CSC) for panic disorder and generalised anxiety disorder in primary
care compared to care as usual (CAU).METHODS:A two armed cluster randomised
controlled trial, 43 primary care practices participated in the study. Patients se-
lected by their general practitioner and patients selected from files screening pos-
itive on an anxiety screener, had a MINI International Neuropsychiatric Interview
to classify DSM-IV disorders. Eventually, 180 patients with a diagnosis of panic
disorder or generalised anxiety disorder were included in the study (114 collabor-
ative stepped care, 66 care as usual). Baseline measurements and follow up mea-
sures (3, 6, 9 and 12 months) were assessed using questionnaires. We applied the
TiC-P and the EQ-5D respectively assessing the health care utilization, production
losses and general health related quality of life. The incremental analysis indicated
costs per QALY. RESULTS: The average annual direct medical costs in the collab-
orative stepped care group were 1987 Euro (sd 2027), compared to 1645 Euro (sd
1844) in the care as usual group. The average quality of life years (QALY’s) gained
was higher in the collaborative stepped care group compared to the care as usual
group, 0.08 QALY. The incremental cost utility was about 4100 euro per QALY.
Including both the direct medical costs and productivity costs the collaborative
stepped care group dominated CAU. CONCLUSIONS: The study showed that CSC is
a cost effective intervention for anxiety disorder in the primary care setting and
even dominant including productivity costs.
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OBJECTIVES: Despite the availability of numerous antidepressants, persistence
with treatment is poor and adverse events are a key factor. Agomelatine is a new
chemical entity for the treatment of major depressive disorders (MDD) with a pla-
cebo-like side effect profile resulting in a statistically significantly higher propor-
tion of patients continuing treatment compared with venlafaxine. The objective of
this study was to conduct a cost-utility analysis of agomelatine compared with
venlafaxine from an Australian healthcare perspective to inform reimbursement
decision making by the Pharmaceutical Benefits Advisory Committee (PBAC).
METHODS: An Excel-based Markov model was developed with four states ‘de-
pressed’, ‘remission’, ‘well’ and ‘death’ with a three year time-horizon. Agomela-
tine and venlafaxine were assumed to be equally effective in the treatment of
depressive symptoms but to differ in discontinuation rates, requirement for down
titration and costs. Patients enter the model in the ‘depressed’ state and can prog-
ress to ‘remission’ where they may relapse and re-enter ‘depressed’ or move to the
‘well’ state (after spending six months in ‘remission’). Patients in the ‘depressed’ or
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